Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07264010 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Name: Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study — clinical trial record (NCT07264010)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorNanfang Hospital, Southern Medical University

Started2025-12-01

View on ClinicalTrials.gov ↗

Nanfang Hospital, Southern Medical University

182 trials monitored

See 2 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Myeloid Leukemia (AML)

1,196 trials monitored

See 63 trials at risk

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

Trial Details

NCT Number	NCT07264010
Lead Sponsor	Nanfang Hospital, Southern Medical University
Conditions	Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
Enrollment	87 participants
Start Date	2025-12-01
Primary Completion	2026-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-04